Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
42
Recruiting, any sponsor type, condition "amyotrophic lateral sclerosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed245
42 trials
Showing 1 to 25, recently updated first.
- A Study of Ranolazine in ALSRecruiting
Swathy Chandrashekhar, MBBSAcademic, hospital or other
NCT06527222 · 72 participants (planned) · Start Apr 29, 2025 · Primary completion Jul 2028
Drug: Ranolazine; Ranolazine and 1 more · For: Amyotrophic Lateral Sclerosis
Sites: San Francisco, California; Jacksonville, Florida; Fairway, Kansas · 6 sites in all
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPivotal-lookingRecruiting
PrileniaIndustry
NCT07322003 · 500 participants (planned) · Start Feb 1, 2026 · Primary completion Mar 2028
Drug: Pridopidine; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Francisco, California; Aurora, Colorado · 56 sites in all
Vector Y TherapeuticsIndustry
NCT07287397 · 36 participants (planned) · Start Dec 19, 2025 · Primary completion Oct 15, 2027
Drug: Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Diego, California; Jacksonville, Florida · 9 sites in all
BiogenBiogen (BIIB)
NCT07855211 · 69 participants (planned) · Start Oct 7, 2026 · Primary completion Jan 23, 2034
Drug: BIIB147; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Scottsdale, Arizona; St Louis, Missouri; Austin, Texas
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07100119 · 36 participants (planned) · Start Aug 5, 2025 · Primary completion Aug 2027
Drug: LY4256984; Placebo · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Leuven, Belgium; Calgary, Canada; Edmonton, Canada · 12 sites in all
Trace Neuroscience, Inc.Industry
NCT07674667 · 30 participants (planned) · Start Aug 20, 2026 · Primary completion Sep 2027
Drug: TRCN-1023 · For: Amyotrophic Lateral Sclerosis
Sites: Lübeck, Germany; Munich, Germany; Rostock, Germany · 6 sites in all
- A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALSRecruiting
Oliver BlanchardAcademic, hospital or other
NCT06249867 · 60 participants (planned) · Start Nov 8, 2024 · Primary completion Oct 2027
Drug: Darifenacin 7.5 MG Extended Release Oral Tablet; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Ottawa, Canada; Montreal, Canada
- Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALSPivotal-lookingRecruiting
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT06126315 · 246 participants (planned) · Start Mar 26, 2025 · Primary completion Apr 2027
Drug: Acetyl-l-carnitine; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Sydney, Australia; Brescia, Italy; Bergamo, Italy · 19 sites in all
Talengen Institute of Life Sciences, Shenzhen, P.R. China.Academic, hospital or other
NCT06726577 · 60 participants (planned) · Start Jun 4, 2026 · Primary completion Jan 2027
Drug: TP04HN106; Saline · For: Amyotrophic Lateral Sclerosis
Sites: Suzhou, China
- Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)Recruiting
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT07204977 · 30 participants (planned) · Start Feb 2, 2026 · Primary completion Sep 30, 2027
Drug: Acamprosate calcium · For: Amyotrophic Lateral Sclerosis; Motor Neuron Disease
Sites: Bethesda, Maryland
- RAPA-501 Therapy for ALSPivotal-lookingRecruiting
Rapa Therapeutics LLCIndustry
NCT04220190 · 41 participants (planned) · Start Jan 2, 2025 · Primary completion Jul 1, 2027
Drug: RAPA-501 Autologous T stem cells · For: Amyotrophic Lateral Sclerosis
Sites: Boston, Massachusetts
Eli Lilly and CompanyEli Lilly (LLY)
NCT07571174 · 32 participants (planned) · Start May 14, 2026 · Primary completion Jun 2029
Drug: LY4256984 · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Calgary, Canada; London, Canada · 11 sites in all
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingRecruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07082192 · 240 participants (planned) · Start Oct 30, 2025 · Primary completion Sep 30, 2027
Drug: Test drug CB03-154 5mg group; Test drug CB03-154 10mg group and 2 more · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Beijing, China
Eli Lilly and CompanyEli Lilly (LLY)
NCT07571200 · 32 participants (planned) · Start May 14, 2026 · Primary completion Jun 2029
Drug: LY4256984 · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Calgary, Canada; London, Canada · 11 sites in all
Nura BioIndustry
NCT07369076 · 80 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 2027
Drug: NB-4746 High dose; NB-4746 Low dose and 2 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Concord, Australia; Randwick, Australia; Brisbane, Australia · 12 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06351592 · 54 participants (planned) · Start Aug 28, 2024 · Primary completion Mar 21, 2032
Drug: ALN-SOD; Placebo (PB) · For: Amyotrophic Lateral Sclerosis (ALS); Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Sites: Concord, Australia; Sydney, Australia; Birtinya, Australia · 22 sites in all
University of IowaAcademic, hospital or other
NCT07224269 · 20 participants (planned) · Start Aug 12, 2026 · Primary completion Aug 1, 2027
Drug: Terazosine; Placebo · For: Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities
Sites: Iowa City, Iowa
- Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07023835 · 240 participants (planned) · Start Sep 17, 2025 · Primary completion Mar 2028
Drug: 50 mg Usnoflast; 75 mg Usnoflast and 1 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: La Jolla, California; Orange, California; San Francisco, California · 49 sites in all
Leal Therapeutics, IncIndustry
NCT07660614 · 56 participants (planned) · Start Apr 29, 2026 · Primary completion Jun 2031
Drug: LTX-002 · For: Amyotrophic Lateral Sclerosis
Sites: Lübeck, Germany; Milan, Italy; Torino, Italy · 5 sites in all
Johns Hopkins UniversityAcademic, hospital or other
NCT06656702 · 24 participants (planned) · Start Apr 9, 2025 · Primary completion Jan 30, 2027
Drug: Psilocybin · For: Amyotrophic Lateral Sclerosis
Sites: Baltimore, Maryland
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSPivotal-lookingRecruiting
PhenoNet, Inc.Industry
NCT07142291 · 105 participants (planned) · Start Nov 25, 2025 · Primary completion Mar 2027
Drug: Cromolyn Sodium (34.2 mg BID); Cromolyn Sodium (17.1 mg BID) and 2 more · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Scottsdale, Arizona; La Jolla, California; San Francisco, California · 22 sites in all
- Intestinal Microbiome Transplant in ALSRecruiting
Duke UniversityAcademic, hospital or other
NCT07017946 · 20 participants (planned) · Start Jan 27, 2026 · Primary completion Nov 1, 2026
Drug: MTP-101C · For: Amyotrophic Lateral Sclerosis ALS
Sites: Durham, North Carolina
- Tofersen in Non-SOD1 ALSRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07294144 · 30 participants (planned) · Start Dec 29, 2025 · Primary completion Jan 2027
Drug: Tofersen · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Atlanta, Georgia; Boston, Massachusetts; St Louis, Missouri
Healing Advocates Registry and MinistryAcademic, hospital or other
NCT07233148 · 1,000 participants (planned) · Start Jan 26, 2026 · Primary completion Feb 5, 2036
Drug: ALS medications and other medications · For: Amyotrophic Lateral Sclerosis (ALS); Motor Neuron Disease (MND); Primary Lateral Sclerosis (PLS)
Sites: Park City, Utah
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.